SEC Form 4/A · accession 0001209191-15-005649
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Andrew R Allen
Officer — See Remarks
Period of report
Jan 15, 2015
Accepted (ET)
Jan 21, 2015 · 9:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 15, 2015 | S | 300 | $65.00 | D | 181,619 | D | |
| Common StockF1,F2 | Jan 16, 2015 | S | 30,524 | $65.2675 | D | 151,095 | D | |
| Common StockF1,F3 | Jan 16, 2015 | S | 49,176 | $66.2553 | D | 101,919 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2014.
- F2The price reported reflects the weighted average sale price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $65.00 to $65.94, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported reflects the weighted average sale price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $66.01 to $67.00, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Remarks
Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer This Form 4/A restates the weighted average sale price of the shares sold by the Reporting Person within the price range set forth in footnote (3).